Download Free Medical Molecular and Genomic Driven Trials Precision Medicine PowerPoint Presentation

Molecular and Genomic Driven Trials Precision Medicine PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical PowerPoint presentation titled "Molecular & Genomic driven trials Precision Medicine" by Mustafa Khasraw.

This medical PowerPoint presentation tells us how molecular and genomic-driven trials are an important part of precision medicine.

Molecular and genomic-driven trials are a type of clinical trial that uses molecular and genetic information to match patients with specific treatments. Precision medicine, which is also known as personalized medicine, is a medical approach that tailors treatments to an individuals unique genetic makeup, lifestyle, and environment.

Precision medicine aims to provide more effective treatments that are tailored to a patients specific needs, rather than a one-size-fits-all approach. It uses molecular and genomic information to identify patients who are most likely to benefit from a particular treatment, and to determine the optimal dose and duration of treatment.

Molecular and genomic-driven trials are a key component of precision medicine, as they allow researchers to identify which treatments are most effective for different genetic subtypes of a disease. By analyzing a patients genetic profile, doctors can predict which drugs are likely to be effective, which may have adverse effects, and which may not work at all.

These trials often use advanced genomic technologies, such as DNA sequencing, to identify genetic mutations and other molecular markers that are associated with a particular disease. This information is then used to design clinical trials that test new treatments or combinations of treatments in patients who have specific genetic mutations or other molecular characteristics.

In summary, molecular and genomic-driven trials are an important part of precision medicine, which aims to provide tailored treatments that are more effective and have fewer side effects than traditional approaches. By using advanced genomic technologies to analyze a patients genetic profile, doctors can identify which treatments are most likely to be effective and tailor treatment plans accordingly.

Tags : molecular and genomic-driven trials, precision medicine, personalized medicine, pharmaceuticals, pharmaceuticals PowerPoint presentations

Published on : Jun 23, 2023 | Views : 533 | Downloads : 0

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Molecular & Genomic driven trials Precision Medicine Mustafa Khasraw Medical Oncologist @ RNSH Clinical Lead @ the NHMRC Clinical Trials Centre
Slide 2-

Prevention and treatment strategies that take individual variability into account Precision Medicine (PM) Personalized Medicine Creation of medical treatments unique to the particular patient
Slide 3-

In 2015, the Precision Medicine Initiative was launched by the US government through the National Institute of Health with a US$215M budget to accelerate implementation of precision medicine into standard clinical practice In 2018, the Australian Genomics Health Futures Mission was launched by the with a AU$500M budget as part of the National Health and Medical Industry Growth Plan and the aim to enable practitioners to tailor treatment for each patients through genomics technology and precision medicine innovation Why Precision Medicine?
Slide 4-

Prospect of PM improved by: Large-scale biologic databases (such as the human genome sequence) Patient characterization: proteomics, metabolomics, genomics, cellular assays Health technology Computational tools/ large data sets Precision Medicine
Slide 5-

ppt slide no 5 content not found
Slide 6-

Hugo Fitipaldi et al. Diabetes 2018;67:1911-1922 PM in type 2 DM
Slide 7-

Many cancers driven by molecular aberrations? Each cancer has own signature, with tumor-specific features and features common to multiple tumors? Cancers are a consequence of accumulating genomic damage? Inherited genetic variations contribute to cancer risk? This understanding has influenced risk assessment, diagnostic categories, and therapeutic strategies? Drugs and antibodies have been developed designed to counter specific molecular drivers? Molecular signatures may be strong predictors of benefit? Oncology is well suited for PM?
Slide 8-

ppt slide no 8 content not found
Slide 9-

Karapetis CS et al. N Engl J Med 2008;359:1757-1765. Kaplan–Meier Curves for Overall Survival According to Treatment.
Slide 10-

ppt slide no 10 content not found
Slide 11-

ppt slide no 11 content not found
Slide 12-

ppt slide no 12 content not found
Slide 13-

Precision and The Person Precision Medicine Personalized Medicine The Premise, The Promise and The Hype!
Slide 14-

Precision and The Person Precision Medicine Personalized Medicine The Premise, The Promise and The Hype! ? Complexity ? Gene networks ? Epigenetics ? The Interactome ? Heterogeneity ? Point Mutations (HER2, EGFR, c-kit, ALK…etc) ? Oncogene addiction
Slide 15-

NEAR TERM GOALS Innovative clinical trial design Use of combination therapies Overcome drug resistance LONGER TERM GOALS Create cohorts of big data and share Biological samples, diet/ lifestyle, linked to electronic health records* Goals of PM?
Slide 16-

ppt slide no 16 content not found
Slide 17-

Woodcock J, LaVange LM. N Engl J Med 2017;377:62-70. Umbrella Trial and Basket Trial
Slide 18-

Standard protocol vs Common Control CONTROL DRUG A VS CONTROL DRUG B CONTROL DRUG C CONTROL DRUG D CONTROL DRUG E CONTROL DRUG A
Slide 19-

Master protocol: provides additional efficiencies (especially if harmonization of endpoints) CONTROL DRUG A DRUG B DRUG C DRUG D DRUG E
Slide 20-

CONTROL DRUG A DRUG B DRUG C DRUG D DRUG E 1M 1U R
Slide 21-

1M 1U R CONTROL DRUG A DRUG B DRUG C DRUG D DRUG E SUBTYPES
Slide 22-

1M 1U R CONTROL DRUG A DRUG B DRUG C DRUG D DRUG E SIGNATURES
Slide 23-

1M 1U R 1M 1U R CONTROL DRUG A DRUG B DRUG C DRUG D DRUG E SUBTYPES
Slide 24-

1M 1U R 1M 1U R CONTROL DRUG A DRUG B DRUG C DRUG D DRUG E SIGNATURES
Slide 25-

1M 1U R 1M 1U R CONTROL DRUG A DRUG B DRUG C DRUG D DRUG E SIGNATURES
Slide 26-

Fixed Randomization Adaptive Randomization STAGE 1 STAGE 2 Fixed Randomization .20 .16 .16 .16 16 .16 CONTROL DRUG A DRUG B DRUG C DRUG D DRUG E
Slide 27-

Fixed Randomization Adaptive Randomization STAGE 1 STAGE 2 Fixed Randomization CONTROL DRUG A DRUG B DRUG C DRUG D DRUG E 1M Drug A Drug B Drug C Drug D Drug E .20 .08 .12 .24 .16 .20
Slide 28-

R Drug A Drug B Drug C Drug D Drug E Fixed Randomization Adaptive Randomization STAGE 1 STAGE 2 Fixed Randomization CONTROL DRUG A DRUG B DRUG C DRUG D DRUG E .20 .16 .00 .36 .08 .20
Slide 29-

Fixed Randomization Adaptive Randomization STAGE 1 STAGE 2 Fixed Randomization X X X CONTROL DRUG A DRUG B DRUG C DRUG D DRUG E
Slide 30-

ppt slide no 30 content not found